Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market
This article was originally published in The Pink Sheet Daily
FDA okays the opioid, which contains abuse-resistant components, with labeling about a study that found the drug less likeable than immediate-release oxycodone.
You may also be interested in...
The latest drug development news and US FDA highlights from our Performance Tracker.
Agency says it is seeing confusion in the marketplace when it comes to distinguishing between agency-approved labeling claims and advertising about products that are intended to be abuse deterrent.
The sponsor believes its data package could support a labeling claim that the drug “is expected to result in a meaningful reduction in abuse”; the agency’s review could indicate the strength of data needed to support such a claim.